119 related articles for article (PubMed ID: 7140004)
21. Clinical pharmacokinetics of 6-hour infusion of high-dose methotrexate. Preliminary trial of monitoring high infusion doses.
Luyckx M; Cazin JL; Brunet C; Gosselin P; Demaille MC
Eur J Clin Pharmacol; 1985; 28(4):457-62. PubMed ID: 3839754
[TBL] [Abstract][Full Text] [Related]
22. Methotrexate Associated Renal Impairment Is Related to Delayed Elimination of High-Dose Methotrexate.
Yang SL; Zhao FY; Song H; Shen DY; Xu XJ
ScientificWorldJournal; 2015; 2015():751703. PubMed ID: 26185782
[TBL] [Abstract][Full Text] [Related]
23. [Investigation on individualized adjustment of target range of high-dose methotrexate].
Hua Y; Zhao WH; Lu XT; Yang LH; Lu W
Zhonghua Er Ke Za Zhi; 2008 Mar; 46(3):203-8. PubMed ID: 19099710
[TBL] [Abstract][Full Text] [Related]
24. Methotrexate-vindesine association in the treatment of head and neck cancer influence of vindesine on methotrexate's pharmacokinetic behavior.
Lena N; Imbert AM; Pignon T; Favre R; Meyer G; Cano JP; Carcassonne Y
Cancer Chemother Pharmacol; 1984; 12(2):120-4. PubMed ID: 6697425
[TBL] [Abstract][Full Text] [Related]
25. The effect of prior cisplatin therapy on the pharmacokinetics of high-dose methotrexate.
Crom WR; Pratt CB; Green AA; Champion JE; Crom DB; Stewart CF; Evans WE
J Clin Oncol; 1984 Jun; 2(6):655-61. PubMed ID: 6539365
[TBL] [Abstract][Full Text] [Related]
26. Distribution of methotrexate between plasma and peripheral lymph in man.
Sand TE; Engeset A; Solheim OP; Jacobsen S
Lymphology; 1978 Dec; 11(4):181-5. PubMed ID: 739791
[TBL] [Abstract][Full Text] [Related]
27. Renal excretion and pharmacokinetics of methotrexate and 7-hydroxy-methotrexate following a 24-h high dose infusion of methotrexate in children.
Winograd B; Lippens RJ; Oosterbaan MJ; Dirks MJ; Vree TB; van der Kleijn E
Eur J Clin Pharmacol; 1986; 30(2):231-8. PubMed ID: 3709652
[TBL] [Abstract][Full Text] [Related]
28. [Effects of infusion duration of high-dose methotrexate on cerebrospinal fluid drug levels in lymphoma patients].
Lin XB; Zhou NN; Li S; Cai QQ; Xia ZJ; Liao H; Gao Y; Huang HQ
Ai Zheng; 2008 Oct; 27(10):1100-5. PubMed ID: 18851792
[TBL] [Abstract][Full Text] [Related]
29. The safety of administration of massive doses of methotrexate (50 g) with equimolar citrovorum factor rescue in adult patients.
Reggev A; Djerassi I
Cancer; 1988 Jun; 61(12):2423-8. PubMed ID: 3259154
[TBL] [Abstract][Full Text] [Related]
30. 5-Fluorouracil and methotrexate administered simultaneously as a continuous infusion. A phase I study.
Lokich JJ; Phillips D; Green R; Paul S; Sonneborn H; Zipoli TE; Curt G
Cancer; 1985 Nov; 56(10):2395-8. PubMed ID: 4042072
[TBL] [Abstract][Full Text] [Related]
31. The role of 7-hydroxymethotrexate during methotrexate anti-cancer therapy.
Lankelma J; van der Klein E; Ramaekers F
Cancer Lett; 1980 Apr; 9(2):133-42. PubMed ID: 7189691
[TBL] [Abstract][Full Text] [Related]
32. Phase II clinical trial with high-dose methotrexate therapy and citrovorum factor rescue.
Isacoff WH; Eilber F; Tabbarah H; Klein P; Dollinger M; Lemkin S; Sheehy P; Cone L; Rosenbloom B; Sieger L; Block JB
Cancer Treat Rep; 1978 Sep; 62(9):1295-304. PubMed ID: 356984
[TBL] [Abstract][Full Text] [Related]
33. Effect of probenecid on cerebrospinal fluid methotrexate kinetics.
Howell SB; Olshen RA; Rice JA
Clin Pharmacol Ther; 1979 Nov; 26(5):641-6. PubMed ID: 498706
[TBL] [Abstract][Full Text] [Related]
34. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients.
Joerger M; Huitema AD; van den Bongard HJ; Baas P; Schornagel JH; Schellens JH; Beijnen JH
Br J Clin Pharmacol; 2006 Jul; 62(1):71-80. PubMed ID: 16842380
[TBL] [Abstract][Full Text] [Related]
35. [A pharmacokinetic study on high-dose methotrexate administration--the effects of volume changes of parenteral solutions on the elimination rate].
Yoshioka S; Tsukamoto T; Nakano M; Oka S; Nakano M; Norimatsu H
Gan To Kagaku Ryoho; 1994 Jan; 21(1):97-102. PubMed ID: 8291921
[TBL] [Abstract][Full Text] [Related]
36. [A device for rapid elevation of plasma methotrexate (MTX) concentration and its maintenance in high-dose MTX therapy].
Miyauchi Y; Mii Y; Morishita T; Miura S; Honoki K; Aoki M; Kido A; Tamai S; Hino M; Nomura Y; Nakanishi E
Gan To Kagaku Ryoho; 1996 Apr; 23(5):595-9. PubMed ID: 8678518
[TBL] [Abstract][Full Text] [Related]
37. Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine.
Abelson HT; Fosburg MT; Beardsley GP; Goorin AM; Gorka C; Link M; Link D
J Clin Oncol; 1983 Mar; 1(3):208-16. PubMed ID: 6607976
[TBL] [Abstract][Full Text] [Related]
38. [Severe renal impairment of methotrexate elimination after high dose therapy].
Lawrenz-Wolf B; Wolfrom C; Frickel C; Fengler R; Wehinger H; Henze G
Klin Padiatr; 1994; 206(4):319-26. PubMed ID: 7967432
[TBL] [Abstract][Full Text] [Related]
39. [Clinical significance of non-renal elimination mechanisms of methotrexate (MTX)].
Erttmann R; Gkanatsas A
Monatsschr Kinderheilkd; 1985 Aug; 133(8):516-9. PubMed ID: 3876505
[TBL] [Abstract][Full Text] [Related]
40. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society.
Hartung G; Stehle G; Sinn H; Wunder A; Schrenk HH; Heeger S; Kränzle M; Edler L; Frei E; Fiebig HH; Heene DL; Maier-Borst W; Queisser W
Clin Cancer Res; 1999 Apr; 5(4):753-9. PubMed ID: 10213209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
